
    
      This is a Phase 3 global, randomized, open-label study comparing LOXO-305 (Arm A) to
      investigator's choice of ibrutinib, acalabrutinib or zanubrutinib (Arm B) in MCL patients who
      have received 1 or more lines of therapy and are BTK inhibitor na√Øve.
    
  